BR9401321A - Muteína, sequência de DNA, vetor, célula, sequência de RNA composto, processo para sua preparação, composição farmacêutica e uso. - Google Patents

Muteína, sequência de DNA, vetor, célula, sequência de RNA composto, processo para sua preparação, composição farmacêutica e uso.

Info

Publication number
BR9401321A
BR9401321A BR9401321A BR9401321A BR9401321A BR 9401321 A BR9401321 A BR 9401321A BR 9401321 A BR9401321 A BR 9401321A BR 9401321 A BR9401321 A BR 9401321A BR 9401321 A BR9401321 A BR 9401321A
Authority
BR
Brazil
Prior art keywords
mutein
vector
cell
preparation
pharmaceutical composition
Prior art date
Application number
BR9401321A
Other languages
English (en)
Inventor
David Banner
Werner Lesslauer
Hansruedi Loetscher
Dietrich Stueber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9401321A publication Critical patent/BR9401321A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
BR9401321A 1993-03-29 1994-03-28 Muteína, sequência de DNA, vetor, célula, sequência de RNA composto, processo para sua preparação, composição farmacêutica e uso. BR9401321A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93810224 1993-03-29

Publications (1)

Publication Number Publication Date
BR9401321A true BR9401321A (pt) 1994-10-18

Family

ID=8214942

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9401321A BR9401321A (pt) 1993-03-29 1994-03-28 Muteína, sequência de DNA, vetor, célula, sequência de RNA composto, processo para sua preparação, composição farmacêutica e uso.

Country Status (14)

Country Link
US (1) US5597899A (pt)
EP (1) EP0619372A1 (pt)
JP (1) JPH089976A (pt)
CN (1) CN1099802A (pt)
AU (1) AU5901994A (pt)
BR (1) BR9401321A (pt)
CA (1) CA2119089A1 (pt)
CZ (1) CZ67694A3 (pt)
FI (1) FI941459A (pt)
HU (1) HUT68218A (pt)
IL (1) IL109094A0 (pt)
NO (1) NO941142L (pt)
NZ (1) NZ260146A (pt)
RU (1) RU94009852A (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1233189A (zh) * 1996-05-08 1999-10-27 弗·哈夫曼-拉罗切有限公司 用TNFR-Ig治疗哮喘
NZ337955A (en) * 1997-04-15 2000-09-29 Ferring Farma Lab Modified TNF-alpha and their use as vaccines
CN1062274C (zh) * 1997-10-07 2001-02-21 复旦大学 人肿瘤坏死因子α衍生物及其制备方法
US6354297B1 (en) * 1998-04-16 2002-03-12 The Uniformed Services University Of The Health Sciences Method and device for destroying fat cells by induction of programmed cell death
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US7244823B2 (en) * 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US7662367B2 (en) * 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
CA2472049A1 (en) * 2002-01-04 2003-07-17 Xencor Dominant negative proteins and methods thereof
US7179891B2 (en) * 2002-03-25 2007-02-20 Tadanori Mayumi Physiologically active complex
JP4177604B2 (ja) * 2002-03-25 2008-11-05 株式会社林原生物化学研究所 生理活性複合体
RU2377253C2 (ru) * 2002-12-02 2009-12-27 Амген Фремонт,Инк. Антитела, специфичные к фактору некроза опухолей, и их применение
MXPA05006945A (es) * 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor.
US7642340B2 (en) * 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
EP2327723A3 (en) 2003-10-10 2012-06-27 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
TW200526780A (en) * 2004-01-06 2005-08-16 Hayashibara Biochem Lab TNF antagonists and TNF inhibitors comprising the same as the active ingredient
PT1949915E (pt) * 2004-04-30 2012-11-27 Biopheresis Technologies Inc Método e sistema para remover rfnt1,rfnt2, e ril2 solúveis em pacientes
GB0425972D0 (en) 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
WO2008127515A1 (en) * 2007-03-01 2008-10-23 Cytologic, Inc. Compositions and method for enhancing immune responses in mammals
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN106540252B (zh) * 2016-12-07 2020-04-28 四川大学 针对肿瘤坏死因子α的蛋白疫苗及其用途
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
US11142558B2 (en) * 2017-04-06 2021-10-12 Universität Stuttgart Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity
EP4355381A1 (en) 2021-06-17 2024-04-24 Immunicom, Inc. Modified tnf as a capture ligand

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE19975063I2 (de) * 1984-03-06 2005-08-18 Dainippon Pharmaceutical Co DNS den menschlichen Tumornekrosisfaktor kodierendund das menschliche Tumornekronisfaktor-Polypepti d.
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
GR851626B (pt) * 1984-07-05 1985-11-26 Genentech Inc
DE3750056T2 (de) * 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
JPH07106158B2 (ja) * 1986-12-04 1995-11-15 サントリー株式会社 抗腫瘍活性を有する新規ポリペプチドおよびその製造法
AU1346488A (en) * 1987-02-26 1988-09-26 Cetus Corporation Arginine-depleted human tumor necrosis factor
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
CA2055168A1 (en) * 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
SK376492A3 (en) * 1992-04-02 1995-06-07 Hoffmann La Roche Tnf - muteins and method of their production

Also Published As

Publication number Publication date
HU9400829D0 (en) 1994-06-28
NO941142D0 (no) 1994-03-28
NO941142L (no) 1994-09-30
RU94009852A (ru) 1996-07-20
CA2119089A1 (en) 1994-09-30
AU5901994A (en) 1994-10-06
JPH089976A (ja) 1996-01-16
IL109094A0 (en) 1994-06-24
FI941459A0 (fi) 1994-03-29
EP0619372A1 (en) 1994-10-12
FI941459A (fi) 1994-09-30
CN1099802A (zh) 1995-03-08
HUT68218A (en) 1995-06-28
CZ67694A3 (en) 1995-02-15
US5597899A (en) 1997-01-28
NZ260146A (en) 1995-10-26

Similar Documents

Publication Publication Date Title
BR9401321A (pt) Muteína, sequência de DNA, vetor, célula, sequência de RNA composto, processo para sua preparação, composição farmacêutica e uso.
BR9301420A (pt) Muteina de fator de necrose,sequencia de dna,vetor,celula hospedeira,composto,processo para sua preparacao,composicao farmaceutica e uso
BR9810116B1 (pt) composição de solução e processo para sua preparação.
FI111263B (fi) Uudet erytromysiinijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö lääkkeinä sekä menetelmässä käytettävät välituoteamiinit
BR9808422B1 (pt) composto, composiÇço farmacÊutica, uso de um composto, e, processo para a preparaÇço de um composto.
BR9804378B1 (pt) compostos, processo para sua produção e uso.
BR9810802B1 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto.
BR9200951A (pt) Compostos, processo para sua producao,preparacoes farmaceuticas e uso
FI953743A0 (fi) Keratolyyttistä ja/tai finnitaudinvastaista aktiivisuutta omaavia kosmeettisia koostumuksia, niiden valmistus ja käyttö
BR9909995B1 (pt) composto, processo para a preparação de um composto, formulação farmacêutica, e, uso de um composto.
IS5129A (is) Arýlsúlfonýlamínó hýdroxamsýruafleiður, notkun þeirra, ásamt lyfjablöndum
IS5130A (is) Arýlsúlfonýlamínó hýdroxamsýruafleiður, notkun þeirra, ásamt lyfjablöndum
BR9601093A (pt) Pirido(3,2-E)pirazinoas processo para sua preparação medicamentos processo para sua preparação e utilização
BR9404809A (pt) Composto, uso, formulação farmacêutica e processo para preparar um composto
BR9803720B1 (pt) composto de pigmento de quinoxalina-monoazo-acetarilida, processo para a preparação e uso do mesmo.
ITFI930083A1 (it) Composti pirrol-amidinici, processi di preparazione e composizioni farmaceutiche che li contengono.
BR9600147A (pt) Purin-6-onas 2,9-DI-substituidas processo para sua preparação medicamentos e uso
BR9712058B1 (pt) formulações para uso de ivermectina, processo para sua preparação e uso.
BR9807682B1 (pt) composto, uso do mesmo, composiÇço farmacÊutica, e, processos para preparar um composto.
BRPI9914571B1 (pt) composto, processo para sua preparação, uso do mesmo, bem como composição farmacêutica.
BR9602025A (pt) Composto composição farmacêutica uso e processo para a preparação de um composto
NO20003661L (no) Nye pentasakkarider, fremgangsmÕter for deres fremstilling og farmasøytiske preparater inneholdende de samme
EE04398B1 (et) Asendatud 1,2,3,4,5,6-heksahüdro-2,6-metano-3-bensasotsiin-10-oolid, nende valmistamise meetod ja kasutamine ravimitena
NO974934D0 (no) 10,13,15-trioksatrisyklo[9.2.1.19.6]pentadekanonderivater, fremgangsmåte for deres fremstilling og legemidler som inneholder disse forbindelsene
IT1297022B1 (it) Complesso di ferro-succinilcaseina, processo per la sua preparazione e composizioni farmaceutiche che lo contengono

Legal Events

Date Code Title Description
FA Application withdrawn
B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: C12N 15/11; C07H 21/04; C07K 7/10; C12P 21/02; C12N 15/63; A61K 37/02.

Ipc: C07K 14/525 (2006.01), A61K 38/00 (2006.01)

Ipc: C07K 14/525 (2006.01), A61K 38/00 (2006.01)